Assessment of Time and Practice Resources Required to Provide Weekly or Monthly Erythropoiesis-Stimulating Protein Therapy to Chronic Kidney Disease Patients in the Physician Office Setting-Reference-Cited by-同舟云学术

Assessment of Time and Practice Resources Required to Provide Weekly or Monthly Erythropoiesis-Stimulating Protein Therapy to Chronic Kidney Disease Patients in the Physician Office Setting

Published:2006-12 Issue:9 Volume:12 Page:714-725
ISSN:1083-4087
Container-title:Journal of Managed Care Pharmacy
language:en
Short-container-title:JMCP

Author:

Bernardo Marializa,Crawford Paul,Hertel Joachim,Sholer Chris,Xu Xiao,Gross Thomas,Kewalramani Reshma,Globe Denise

Publisher

Academy of Managed Care Pharmacy

Subject

Health Policy,Pharmaceutical Science,Pharmacy

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and cost-effectiveness of darbepoetin alfa once every 4 weeks versus continuous erythropoietin receptor activator once every 4 weeks for anemia correction in patients with chronic kidney disease not on dialysis;Kidney Research and Clinical Practice;2024-05-31

2. Costs associated with the administration of erythropoiesis-stimulating agents for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease: a US societal perspective;Journal of Managed Care & Specialty Pharmacy;2021-12

3. Cost-Minimisation Analysis of Erythropoiesis-Stimulating Agents in the Treatment of Anaemia in Dialysed Patients: A Pilot Study;PharmacoEconomics - Open;2017-03-09

4. Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer – An observational study prospectively recording resource utilization in a Swedish healthcare setting;The Breast;2016-10

5. Time savings of weekly versus three-times-per-week administration of erythropoiesis stimulating agents in United States dialysis patients;Current Medical Research and Opinion;2015-12-02